



Ref: Syn/CS/SE/IP/2025-26/Sept/05

Syngene International Limited

Biocon SEZ, Biocon Park, Plot No. 2 & 3,
Bommasandra Industrial Area, IV Phase,
Jigani Link Road, Bengaluru 560099,
Karnataka, India.

T +91 80 6891 8000

F +91 80 6891 8808

CIN: L85110KA1993PLC014937

www.syngeneintl.com

September 09, 2025

To, The Manager, BSE Limited Corporate Relationship Department Dalal Street, Mumbai – 400 001	To, The Manager, National Stock Exchange of India Limited Corporate Communication Department Bandra (EAST), Mumbai – 400 051
Scrip Code: 539268	Scrip Symbol: SYNGENE

Dear Sir/Madam,

Sub: Investor Presentation

In continuation of our earlier intimation vide reference no. Ref: Syn/CS/SE/Reg 30/2025-26/Sept/03 dated September 04, 2025 and in accordance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the presentation that we will be sharing with the Investors and Analysts at the meeting scheduled today, i.e., September 09, 2025.

Kindly note that no additional information will be disclosed to Analysts or Investors other than the information presented earlier and already available in the public domain.

The above-mentioned Investor Presentation will also be available on the website of the Company www.syngeneintl.com.

This is for your information and records.

Thanking You,

Yours faithfully,

For **SYNGENE INTERNATIONAL LIMITED**

Chethan Yogesh
Company Secretary & Compliance Officer

Enclosed: Investor Presentation.

Syngene

Putting Science to Work

Unit-3 plant visit for Investors – 9th September 2025



Agenda

Sr. no	Timing	Particulars	Led by
I	11:30 AM – 12:15 PM	Tea + Brief Introduction (PPT) of the facility	Deepak Jain (CFO) Himanshu Saxena (Head, Biologics manufacturing)
II	12:15 PM- 1:30 PM	<ul style="list-style-type: none"> Divide participant in 2 groups Visit to Drug Substance unit+ utility and facility round area for each group 	Himanshu Saxena (Head, Biologics manufacturing) Mr. Nainesh Dwivedi (Head, Quality for Unit-3) Mr. Dhaval Trivedi (Head, Program Management, Biologics) Mr. Ram Sarma (DP, Manufacturing plant head) Mr. Satish M (DS Manufacturing plant Head) Mr. Babu V (Engineering & maintenance, Unit-3)
III	1:45 PM- 2:30 PM	Lunch / Buffer Time	
IV	2:45 PM- 3:45 PM	<ul style="list-style-type: none"> Feedback by Investors Interaction / Q&A with CFO / CEO 	Peter Bains (CEO) to join virtually Deepak Jain (CFO)

Syngene Management & Leadership for Unit-3 visit



Peter Bains
Managing Director & CEO

- MD & CEO, Syngene International with over 3 decades of experience the pharmaceutical and biotechnology sectors
- Rejoined Syngene in Feb 2025 post spearheading Syngene's IPO in FY16
- Prior to joining Syngene International, Peter served as Group CEO for Biocon
- Previously worked as CEO and was on the Board of Syngene for almost six years starting 2010 and led the company to its successful public listing in 2015
- Also Served as CEO, Sosei Group, a Japanese listed biopharmaceutical company
- Worked in various Leadership roles for GlaxoSmithKline over a period of 23 years



Deepak Jain
Chief Financial Officer

- CFO, Syngene International with over 25 years of experience
- Joined Syngene in September 2024, Appointed as CFO on Dec 01, 2024
- Oversees the finance, supply chain, legal, secretarial and plays an important role in driving strategy, and enabling organizational growth
- Previous experience as CFO, Ather energy. Prior to that, served as India CFO for First Advantage and for Apple
- Held various leadership roles at Procter & Gamble, and Ernst & Young India



Himanshu Saxena
Head,
Biologics Manufacturing

- Over two decades of expertise in supply chain management, business strategy, and pharmaceutical manufacturing
- Currently serving as Head, Biologics manufacturing. Joined Syngene in January, 2024
- Previous work experience with Cadila and Astra Zeneca Pharma India Ltd

01

Introduction and overview of facility



Background – acquired multimodal biologics facility from Stelis Biopharma with integrated drug substance and commercial DP capability in Dec 2023

Why we acquired



Immediate capacity addition

Syngene's existing capacity was fully utilized post signing 10 year agreement with Zoetis in FY23. Unit-3 added immediate capacity (20 KL of biologics drug substance capacity) with potential for future expansion up to a further 20 KL



Capability enhancement

Facility includes commercial scale, high speed, fill-finish unit – an essential capability for drug product manufacturing

Added drug substance capacity and drug product capability years earlier than our internal capex program



Operational Synergy


Facility is located near to Biocon park which houses Syngene's Biologics labs & other facilities enabling shared leadership and essential functions



Value Buy

State of the art facility acquired at Rs 617 Crores (USD 75 Mn) fully funded through internal accruals and cash

Strengthens Syngene's position in the fastest growing segment of the global CRDMO market



Source : Frost & Sullivan: Independent Market Assessment of the Global and Indian CRDMO Market
* Market size does not include Clinical CRO market

Guidance given at time of acquisition. We are maintaining the guidance for now



Asset turnover of 1x in less than 5 years

\$75m acquisition price

(Acquisition concluded at gross value of Rs 617 crores. Value buy as company recorded Capital reserve due to purchase price < fair value of facility)



\$10m modification capex

(INR 100 Crores to repurpose and revalidate the facility)



\$85m to operationalise



Operating Margin

Minor dilution of operating margins in short term as a result of costs to be incurred in this facility

EBITDA margins expected to be in line with the Company average from FY29



Contribution to PAT

Plant to positively contribute to the bottom line from FY27

Current update and strategic focus - the facility was part capitalized in Q1 FY26.

Focus is to drive integrated projects across human and animal health

Where are we now

- ✓ Received local regulatory approvals in May 2025
- ✓ Part of Unit-3 facility became operational in Q1 FY26
 - 1 out 2 line in DS (8 KL 4*2 KL commissioned)
- ✓ Doing Clinical projects ; delivered a GMP clinical batch of drug substance for a US based client in Q1 FY26
- ✓ Seeing good client traction and response across human and animal health

Strategic focus



Focus on building **pipeline** across human health and animal health



Integrated clinical manufacturing projects (Both Animal & Human health) and **commercial/late-stage** manufacturing of mAbs over time along with drug product capabilities



Innovation for cost efficiency : Reducing cost per gram through process innovation


Bird's Eye View of Syngene Unit-3




Salient features of the multi modal facility comprising end to end DS and DP manufacturing capability

- **Drug Substance (DS) :**
 - 8 KL (4*2 KL) commissioned
 - Feasibility for perfusion
- **Drug Product (DP) :**
 - Commercial scale, high speed, fill-finish unit
 - 2 integrated vials lines: 520 vials/min
 - 250 million vials annual capacity at 2 mL fill volume
 - 2-100 mL fill volume feasibility
 - 2 new isolator lines (100 & 600 vials/min) available for installation
- **Clinical Manufacturing :** 200L/500L/2000L depending on client requirement
- **Quality Control (QC) :** Fully equipped Lab for product quality testing
- **Warehouse :** Large warehouse for accommodating raw materials & consumables


Integration Journey: Acquisition to Operation in 7 Months



Unit – 3 (SU3) Site Master Plan



Area Details	
Plot area	22,000 m² (5.4 Acres)
Block Name	
Block 1	Expansion Area available
Block 2 - DS Block	2 Floors (Ground Floor+ First Floor) First floor (2 wings of 10 KL capacity each) – one DS wing operational now with 8 KL (4*2 KL commissioned)
Block 3	Clinical DS (200L), 2 DP vial lines, QC, Admin
Utility Block 1	Steam, Generator
Utility Block 2	WFI (Water for Injection)

 Facilities to be visited today

02

Site visit to DS / Utilities



Site visit – protocols

- **Clothing: Minimum Gowning, Head cap & Shoe cover**
- **Decorum to be maintained while visiting labs**
- **Please limit Q&A with the technical teams related to infrastructure, technical/plant details etc.**
 - We will have a separate Q&A/feedback session with Peter and Deepak to cover strategic/financial aspects



03

Lunch



04

Feedback/Q&A



Feedback/ Q&A

- Feedback/thoughts on the site, capabilities, infrastructure from investors
- Open Q&A





Syngene

Putting Science to Work

Thank you

© 2025 Syngene International Limited, Bengaluru, India. All Rights Reserved. Syngene believes the information in this document is accurate as of its publication date; such information is subject to change without notice. Syngene acknowledges the proprietary rights of other companies to the trademarks, product names and such other intellectual property rights mentioned in this document. Except as expressly permitted, neither this documentation nor any part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, printing, photocopying, recording or otherwise, without the prior permission of Syngene International Limited and/ or any named intellectual property rights holders under this document.

www.syngeneintl.com

Stay Connected

